Autres langues Scinai Immunotherapeutics Ltd.

Actions

SCNI

US09073Q3039

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 19:05:59 13/07/2026			Varia. 5j.	Varia. 1 janv.
0,2448 ^USD	-2,35%		-8,93%	-65,62%

15/06	Scinai Immunotherapeutics Ltd. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
20/05	Scinai Immunotherapeutics Ltd. nomme Eilon Elmalem au poste de directeur du site CDMO de Yavne, avec effet au 14 juin 2026	CI

Autres langues

15/06	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
20/05	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026
18/05	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
27/04	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
27/04	Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding
24/04	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding
06/04	Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities
06/04	Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform
01/04	Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration
01/04	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
01/04	Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt
19/03	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
16/03	Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price
16/03	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
02/03	Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept
02/03	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
25/02	Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
17/02	Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB.
07/01	Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
02/12	Scinai reports nine-month 2025 results as CDMO growth continues and Nanoabs pipeline advances
02/12	Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
13/11	Scinai Immunotherapeutics Ltd. Announces Board Resignations
06/10/25	Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
06/10/25	Scinai Immunotherapeutics Ltd. Receives Non-Dilutive Grant from Israel Innovation Authority to Expand Fill-and-Finish CDMO Capabilities
10/09/25	Scinai Immunotherapeutics Ltd. announced that it expects to receive $15 million in funding from Yorkville Advisors Global LP